Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.61 |
| ▸ | CA7 | P43166 | 6/20 | 0.61 |
| ▸ | CA9 | Q16790 | 6/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.61 |
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | TYR | P14679 | 3/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 6/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.56 |
| ▸ | F3 | P13726 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.53 |
| ▸ | CA6 | P23280 | 3/20 | 0.53 |
| ▸ | CA5A | P35218 | 3/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547176 | 1.00 | CA12 (0.61) | CA12CA7CA9CA14CA1 | |
| SCHEMBL8359765 | 0.84 | MAPT (0.53) | CA12CA7CA9CA14AKR1B10 | |
| SCHEMBL8359766 | 0.84 | MAPT (0.53) | CA12CA7CA9CA14AKR1B10 | |
| SCHEMBL10719558 | 0.81 | JUN (0.53) | CA12CA7CA9CA14CA1 | |
| SCHEMBL22026690 | 0.81 | F3 (0.62) | F3MAOBP4HBGSK3BBACE1 | |
| SCHEMBL30665840 | 0.81 | AKR1B10 (0.52) | AKR1B10AKR1B1MAOBP4HBMMP2 | |
| SCHEMBL8745007 | 0.81 | APP (0.64) | CA12CA7CA9CA14CA1 | |
| SCHEMBL1478808 | 0.81 | F3 (0.62) | F3MAOBP4HBGSK3BBACE1 | |
| SCHEMBL10891552 | 0.79 | CA12 (0.71) | CA12CA7CA9CA14CA1 | |
| SCHEMBL3314742 | 0.79 | CA12 (0.71) | CA12CA7CA9CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118914337-A | Nb-based2Quick detection mass spectrum method for C metabolite | 北京大学 | 2024-11-08 | — | — | CN | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| CN-110291037-A | For determining the composition and method of the infection level in object | 卫理公会医院 | 2019-09-27 | — | — | CN | disclosed |
| US-20190211299-A1 | END FITTING AND DEVICE FOR SAMPLING COLONIES OF MICROORGANISMS AND SAMPLING PROCESS USING SAME | bioMérieux (FR) | 2019-07-11 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2519664-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-1546118-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | Molecular Probes Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005047901-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION PHOSPHORYLATED MOLECULES | MOLECULAR PROBES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2004042347-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | MOLECULAR PROBES, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CA12 2467/4885CA7 3588/4885CA9 3631/4885 |
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | CA12 2847/4885CA7 3812/4885CA9 3154/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | CA12 2847/4885CA7 3812/4885CA9 3154/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | CA12 2847/4885CA7 3812/4885CA9 3154/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | CA12 2467/4885CA7 3588/4885CA9 3631/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CA12 2467/4885CA7 3588/4885CA9 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.